Study Complete
Sponsor ID
20150253
An study of patients with Ph- chromosome-negative relapsed or refractory acute lymphoblastic leukemia in the US
Study Details
A retrospective chart review study of Philadelphia chromosome-negative R/R ALL patients in the US.
Protocol Summary
Primary Outcome Measures
Treatment patterns in patients with Ph- R/R ALL
Timeframe: 86 months
Drug utilization in patients with Ph- R/R ALL
Timeframe: 86 months
Healthcare resource utilization in patients with Ph- R/R ALL
Timeframe: 86 months
Secondary Outcome Measures
Receipt of allogeneic stem cell transplantation following salvage treatment
Timeframe: 86 Months
Incidence of selected adverse events including cytokine release syndrome, neurologic events, any events resulting in hospitalizations, and other serious adverse events.
Timeframe: 86 Months
Best response to salvage treatment (chemotherapy or blinatumomab) within 8 weeks and within 12 weeks of initiation of salvage treatment.
Timeframe: 12 Weeks
MRD status within 12 weeks of initiation of salvage treatment
Timeframe: 12 Weeks
Overall survival from the time of initiation of salvage treatment
Timeframe: 86 Months
RFS from time remission achieved with salvage treatment
Timeframe: 86 Months
Locations
Location
Research Site
Baltimore, MD, United States, 21201
Status
Recruiting
Location
Research Site
Ames, IA, United States, 50010
Status
Recruiting
Location
Research Site
Detroit, MI, United States, 48201
Status
Recruiting
Location
Research Site
Philadelphia, PA, United States, 19107
Status
Recruiting
Location
Research Site
Duarte, CA, United States, 91010
Status
Recruiting
Location
Research Site
Chicago, IL, United States, 60612
Status
Completed
Showing {first} - {last} of {total} Results